Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

被引：0
|
作者：
Le, X. [1 ]
Eisert, A. [2 ]
Himpe, U. [3 ]
De Bondt, C. [4 ]
Mazieres, J. [5 ]
Petrini, I. [6 ]
Tho, L. M. [7 ]
Ahmad, A. [8 ]
Lam, W. -S. [9 ]
Chik, Y. K. J. [10 ]
Lee, W. C. K. [11 ]
Yang, T. -Y. [12 ]
Joshi, K. [13 ,14 ]
Berghoff, K. [13 ]
Vlassak, S. [13 ]
Karachaliou, N. [13 ]
v. d. Wekken, A. [15 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany
[3] AZ Delta Roeselare Menen Torhout, Roeselare, Belgium
[4] Antwerp Univ Hosp, Edegem, Belgium
[5] Univ Paul Sabatier, CHU Toulouse, Toulouse, France
[6] Univ Hosp Pisa, Pisa, Italy
[7] Pantai Hosp Kuala Lumpur, Kuala Lumpur, Malaysia
[8] Beacon Hosp, Petaling Jaya, Selangor, Malaysia
[9] Western Haematol & Oncol Clin, Perth, Australia
[10] Queen Elizabeth Hosp, Hong Kong, Peoples R China
[11] Prince Wales Hosp, Hong Kong, Peoples R China
[12] Taichung Vet Gen Hosp, Taichung, Taiwan
[13] Merck Healthcare KGaA, Darmstadt, Germany
[14] ICON Plc, Dublin, Ireland
[15] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Tepotinib; EGFR; MET;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-16
引用
收藏
页码：S483 / S484
页数：2
相关论文
共 50 条
  • [1] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [2] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Chung, Wai
    Lee, Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Young, Louise
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    van der Wekken, Anthonie
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
  • [3] Tepotinib with an EGFR-tyrosine kinase inhibitor in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Lee, Wai Chung Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    Young, Louise
    van der Wekken, Anthonie
    [J]. RESPIROLOGY, 2023, 28 : 14 - 15
  • [4] Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series
    Le, Xiuning
    Eisert, Anna
    Hsia, Te-Chun
    Raut, Nirmal Vivek
    Ahmad, Azura
    Chan, Oscar Siu Hong
    De Bondt, Charlotte
    Farrugia, David
    Froesch, Patrizia
    Gonzalez-Cao, Maria
    Hendriks, Lizza
    Hochmair, Maximilian J.
    Mazieres, Julien
    O'Sullivan, Hazel
    Samol, Jens
    van der Wekken, Anthonie J.
    Yang, Tsung-Ying
    Joshi, Kirti
    Vlassak, Soetkin
    Chang, Gee-Chen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [6] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [7] Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
    Park, K.
    Zhou, J.
    Kim, D-W.
    Ahmad, A. R.
    Soo, R. A.
    Bruns, R.
    Straub, J.
    Johne, A.
    Scheele, J.
    Yang, J. C-H.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
    Zhang, Zhe
    Yang, Sen
    Wang, Qiming
    [J]. BIOMARKER RESEARCH, 2019, 7 (01)
  • [9] Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
    Zhe Zhang
    Sen Yang
    Qiming Wang
    [J]. Biomarker Research, 7
  • [10] A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
    Yang, J. -
    Fang, J.
    Shu, Y.
    Chang, J.
    Chen, G.
    He, J.
    Li, W.
    Liu, X.
    Yang, N.
    Zhou, C.
    Huang, J.
    Yang, L.
    Handzel, A.
    Frigault, M.
    Ahmed, G.
    Egile, C.
    Morgan, S.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1769 - S1769
12345